JP2022500426A5 - - Google Patents
Info
- Publication number
- JP2022500426A5 JP2022500426A5 JP2021514022A JP2021514022A JP2022500426A5 JP 2022500426 A5 JP2022500426 A5 JP 2022500426A5 JP 2021514022 A JP2021514022 A JP 2021514022A JP 2021514022 A JP2021514022 A JP 2021514022A JP 2022500426 A5 JP2022500426 A5 JP 2022500426A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- weight
- salt
- hyaluronic acid
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024098708A JP2024137952A (ja) | 2018-09-13 | 2024-06-19 | クロストリジウム毒素－ヒアルロン酸組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862731063P | 2018-09-13 | 2018-09-13 | |
| US62/731,063 | 2018-09-13 | ||
| PCT/US2019/051173 WO2020056371A1 (en) | 2018-09-13 | 2019-09-13 | Clostridial toxin-hyaluronic acid compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024098708A Division JP2024137952A (ja) | 2018-09-13 | 2024-06-19 | クロストリジウム毒素－ヒアルロン酸組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022500426A JP2022500426A (ja) | 2022-01-04 |
| JPWO2020056371A5 JPWO2020056371A5 (https=) | 2022-09-21 |
| JP2022500426A5 true JP2022500426A5 (https=) | 2022-09-21 |
Family
ID=68069925
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021514022A Pending JP2022500426A (ja) | 2018-09-13 | 2019-09-13 | クロストリジウム毒素−ヒアルロン酸組成物 |
| JP2024098708A Pending JP2024137952A (ja) | 2018-09-13 | 2024-06-19 | クロストリジウム毒素－ヒアルロン酸組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024098708A Pending JP2024137952A (ja) | 2018-09-13 | 2024-06-19 | クロストリジウム毒素－ヒアルロン酸組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20200108129A1 (https=) |
| EP (1) | EP3849512A1 (https=) |
| JP (2) | JP2022500426A (https=) |
| KR (2) | KR20210057129A (https=) |
| CN (1) | CN112888454A (https=) |
| AU (1) | AU2019339519A1 (https=) |
| BR (1) | BR112021004771A2 (https=) |
| CA (1) | CA3112394A1 (https=) |
| MX (2) | MX2021002992A (https=) |
| WO (1) | WO2020056371A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9480731B2 (en) * | 2013-12-12 | 2016-11-01 | Medy-Tox, Inc. | Long lasting effect of new botulinum toxin formulations |
| BR112019004935A2 (pt) | 2016-09-13 | 2019-06-04 | Allergan, Inc. | composições de toxina clostridial não proteíca estabilizada |
| CN115397399B (zh) * | 2020-04-08 | 2025-06-27 | 玫帝托克斯股份有限公司 | 一种易于控制排出速度且稳定的肉毒杆菌毒素预填充式注射器剂型 |
| US20240050538A1 (en) * | 2020-12-18 | 2024-02-15 | Atgc Co., Ltd. | Pharmaceutical composition for long-term storage of liquid formulation of botulinum toxin |
| US20250295741A1 (en) | 2022-11-07 | 2025-09-25 | Allergan, Inc. | Prevention of post-operative atrial fibrillation with a botulinum toxin |
| AU2023392523A1 (en) | 2022-12-15 | 2025-04-10 | Merz Pharma Gmbh & Co. Kgaa | Injectable gel comprising botulinum toxin and uses thereof |
| WO2025151741A1 (en) * | 2024-01-10 | 2025-07-17 | Brown David Donaldson | Methods of treating migraine headache or tension headache with hyaluronic acid |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4636524A (en) | 1984-12-06 | 1987-01-13 | Biomatrix, Inc. | Cross-linked gels of hyaluronic acid and products containing such gels |
| US5099013A (en) | 1985-03-12 | 1992-03-24 | Biomatrix, Inc, | Hylan preparation and method of recovery thereof from animal tissues |
| US4713448A (en) | 1985-03-12 | 1987-12-15 | Biomatrix, Inc. | Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues |
| US5143724A (en) | 1990-07-09 | 1992-09-01 | Biomatrix, Inc. | Biocompatible viscoelastic gel slurries, their preparation and use |
| US7758872B1 (en) | 2003-02-07 | 2010-07-20 | Eric Finzi | Method of treating depression |
| WO2006096163A1 (en) | 2005-03-03 | 2006-09-14 | Allergan, Inc. | Animal product free system and process for purifying a botulinum toxin |
| AU2016204034B2 (en) * | 2005-10-06 | 2017-12-21 | Allergan, Inc. | Non-protein stabilized clostridial toxin pharmaceutical compositions |
| US8137677B2 (en) * | 2005-10-06 | 2012-03-20 | Allergan, Inc. | Non-protein stabilized clostridial toxin pharmaceutical compositions |
| US9044477B2 (en) * | 2007-12-12 | 2015-06-02 | Allergan, Inc. | Botulinum toxin formulation |
| US9107815B2 (en) * | 2008-02-22 | 2015-08-18 | Allergan, Inc. | Sustained release poloxamer containing pharmaceutical compositions |
| KR101604515B1 (ko) | 2008-03-14 | 2016-03-17 | 알러간, 인코포레이티드 | 면역-기반 보툴리눔 독소 세로타입 ａ 활성 검정 |
| KR20110106346A (ko) * | 2008-12-10 | 2011-09-28 | 알러간, 인코포레이티드 | 클로스트리디움 독소 약제학적 조성물 |
| MX2011009621A (es) | 2009-03-13 | 2011-12-16 | Allergan Inc | Celulas utiles para ensayos de actividad del serotipo a de la toxina botulinica baados en inmunoensayos. |
| US9480731B2 (en) * | 2013-12-12 | 2016-11-01 | Medy-Tox, Inc. | Long lasting effect of new botulinum toxin formulations |
| MX395130B (es) * | 2016-03-02 | 2025-03-24 | Merz Pharma Gmbh & Co Kgaa | Composicion que comprende toxina botulinica |
| BR112019004935A2 (pt) * | 2016-09-13 | 2019-06-04 | Allergan, Inc. | composições de toxina clostridial não proteíca estabilizada |
-
2019
- 2019-09-13 CA CA3112394A patent/CA3112394A1/en active Pending
- 2019-09-13 JP JP2021514022A patent/JP2022500426A/ja active Pending
- 2019-09-13 KR KR1020217010717A patent/KR20210057129A/ko not_active Ceased
- 2019-09-13 BR BR112021004771A patent/BR112021004771A2/pt not_active IP Right Cessation
- 2019-09-13 CN CN201980069935.6A patent/CN112888454A/zh active Pending
- 2019-09-13 KR KR1020257026240A patent/KR20250124258A/ko active Pending
- 2019-09-13 EP EP19778773.2A patent/EP3849512A1/en not_active Withdrawn
- 2019-09-13 MX MX2021002992A patent/MX2021002992A/es unknown
- 2019-09-13 WO PCT/US2019/051173 patent/WO2020056371A1/en not_active Ceased
- 2019-09-13 AU AU2019339519A patent/AU2019339519A1/en not_active Abandoned
- 2019-09-13 US US16/571,014 patent/US20200108129A1/en not_active Abandoned
-
2021
- 2021-03-12 MX MX2024007080A patent/MX2024007080A/es unknown
-
2022
- 2022-06-30 US US17/854,334 patent/US20230158129A1/en not_active Abandoned
-
2024
- 2024-06-19 JP JP2024098708A patent/JP2024137952A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022500426A5 (https=) | ||
| TWI463978B (zh) | Ophthalmic composition | |
| PE20241346A1 (es) | Vectores del factor viii del virus adeno-asociado, particulas viricas asociadas y formulaciones que los comprenden | |
| US9012503B2 (en) | Ophthalmic composition | |
| JP6527468B2 (ja) | ヒアルロン酸ナトリウムとカルボキシメチルセルロースを含む人工涙液 | |
| ES2349472T3 (es) | Formulación estable de interferón pegilado. | |
| JP2014511847A5 (https=) | ||
| KR20190053884A (ko) | 안정화된 비단백질 클로스트리듐 독소 조성물 | |
| JP2014139229A5 (https=) | ||
| JP2025516814A (ja) | 眼科用局所クリーム組成物および調製物における双性イオンの新規の適用方法 | |
| JP2013514373A (ja) | 非刺激性の眼科用ポビドンヨード組成物 | |
| JP2010539172A5 (https=) | ||
| KR102107471B1 (ko) | 각결막 보호제 또는 각결막 장해 억제제 | |
| US20250188461A1 (en) | Methods of treating osmidrosis | |
| JP2019527711A5 (https=) | ||
| RU2018112239A (ru) | Фармацевтическая композиция на основе трамадола для офтальмологического применения | |
| TWI501764B (zh) | Ophthalmic compositions and methods for inhibiting turbidity and sedimentation | |
| JP2021107464A (ja) | 眼科組成物 | |
| JPWO2020056371A5 (https=) | ||
| TWI351950B (en) | Use of (halobenzyloxy) benzylamino-propanamides fo | |
| AR105111A1 (es) | Composición para administración de agentes activos a un animal | |
| JP2011026303A (ja) | 眼科用組成物及び白濁・沈殿抑制方法 | |
| ES2295161T3 (es) | Solucion oftalmica. | |
| JP2021513521A5 (https=) | ||
| JP4776282B2 (ja) | コンタクトレンズ用組成物 |